NewAmsterdam Pharma (NAMS) stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.
↑ XThis exclusive rating from Investor's Business Daily identifies price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the best-performing stocks tend to have an RS Rating north of 80 at the beginning of a new price run.
Here Are 3 Keys For Successful Stock Investing
NewAmsterdam Pharma stock broke out earlier, but has fallen back below the prior 26.35 entry from a consolidation. If a stock you're watching climbs above a buy point then retreats 7% or more below the original entry price, it's considered a failed base. It's best to wait for the stock to form a new base and breakout. Also understand that the latest pattern is a later-stage base, and such bases are more prone to failure.
The biotech company posted 0% earnings growth in its most recent report. Revenue increased 942%.
NewAmsterdam Pharma stock holds the No. 30 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals (CPRX), ADMA Biologics (ADMA) and Corcept Therapeutics (CORT) are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
YOU MAY ALSO LIKE:
Learn How To Time The Market With IBD's ETF Market Strategy
Find Today's Best Growth Stocks To Watch With IBD 50
Find The Best Long-Term Investments With IBD Long-Term Leaders
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.